What disease does Nilotinib capsule treat?

Nilotinib capsules are mainly used to treat adult patients in the chronic phase or accelerated phase of Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). These patients often have resistance or intolerance to previous treatments, including imatinib. Nilotinib capsules inhibit the activity of tyrosine kinases and interfere with the function of cell cycle regulatory proteins, thereby preventing the proliferation of cancer cells and achieving the effect of treating leukemia.

Nilotinib capsules are particularly suitable for patients who have failed to respond to or cannot tolerate imatinib treatment. Clinical studies have shown that nilotinib has high efficacy in these patients. It can not only inhibit the growth of tumor cells, but also induce cell apoptosis, effectively controlling the development of the disease.

When using nilotinib capsules, you need to pay special attention to some matters. First, for patients with hypokalemia, hypomagnesemia, or long QT syndrome, the use of nilotinib may increase the risk of prolongation of the QT interval and may even lead to sudden death. Therefore, low potassium and low magnesium must be corrected before use and monitored regularly. Secondly, nilotinib should be avoided taking with food. Food should be avoided two hours before taking the medicine and one hour after taking the medicine to ensure full absorption of the medicine.

While taking nilotinib, patients should avoid co-administration of drugs that may prolong the QT interval and strong inhibitors of CYP3A4 to prevent the risk of potential drug interactions.

Nilotinib capsules are an effective drug for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia, especially for patients who are resistant or intolerant to imatinib. However, patients' hematological and electrocardiographic parameters need to be closely monitored during use to ensure safe and effective use.